Drug Trial Radar · NCT05168839
Intraoperative Indocyanine Green Fluorescence Angiography in Colorectal Surgery to Prevent Anastomotic Leakage
Last checked: Nov 19, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,010
Planned (sponsor's estimate)
Start
Sep 26, 2022
Primary completion
Oct 31, 2025
Study completion Oct 31, 2025
Sponsor
- Lead sponsor
- Centre Hospitalier Universitaire de BesanconAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Colorectal cancer (CRC) is the fourth most commonly diagnosed cancer in the world and the third in France. Its incidence is steadily rising in developing nations. Anastomotic leak (AL) is a major problem in colorectal surgery affecting at least 7% of patients operated on for left colonic cancer. It is the most feared complication after colorectal anastomosis, associated with mortality, prolonged hospitalization, impaired health related quality of life (HRQoL) and increased health care costs. Intraoperative fluorescence angiography (IOFA) with indocyanine green (ICG) may help preventing AL. Available studies on the effects of IOFA with ICG are heterogeneous and randomized controlled trial are scarce. Our aim is to demonstrate that IOFA with ICG could lead to a reduction of AL rate after left-sided or low anterior resection with anastomosis for CRC. The FLUOCOL-1 study is the first national, multicenter, single blind, randomized, 2-arm, phase III superiority clinical trial. The primary endpoint is the occurrence of an AL 90 days post-operation. AL is defined as any anastomotic dehiscence with leakage into the pelvic cavity diagnosed upon imaging or at surgical exploration or any isolated pelvic organ-space infection with no evidence of fistula as defined by the International Study Group of Rectal Cancer. The study population will be made of adult patients with left-sided or high rectal cancer scheduled to undergo elective left colectomy or high rectal resection (by open, laparoscopy or robotic surgery) and with expected stapled or hand-sewn intraperitoneal anastomosis. The exclusion criteria are mainly an emergent surgery; rectal cancer requiring total mesorectal excision and anastomosis expected below the peritoneal reflection; CRC requiring total or subtotal colectomy; CRC requiring transverse colectomy; recurrent CRC and locally advanced colorectal cancer requiring multi-visceral excision. A total of 1010 patients will be necessary (39 patients in each centre during 36 months). An interim analysis for efficacy and futility is scheduled when half of the participants will have been recruited. In case of positive results favoring IOFA, this study would define the use of IOFA as a standard of care in colorectal surgery. At the patient level, a significantly lower rate of AL will reduce hospital stay and stoma rate, and will ensure improved postoperative recovery, faster return to normal activity and better long-term oncologic outcomes.
Conditions
- Colorectal Cancer
Interventions
FLUO+ : Intraoperative fluorescence angiography (IOFA) with indocyanine green (ICG).Drug
In the experimental arm (FLUO+), at least one 0.1mg/kg Infracyanine® bolus will be injected intravenously by the anesthesiologist. The detection of indocyanine green in the proximal colon segment will be done open or intracorporeally using a dedicated infrared camera. A surgical film describing the injection technique and fluorescence detection will be presented during the study set-up visits. An additional injection is allowed at the surgeon's discretion if necessary (change of anastomosis site). The time from injection to indocyanine green detection and any adverse events will be recorded.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Anastomotic leakage 90 days after surgeryTime frame: 90 days after surgery
Locations
32 sites in 1 country. Site status is shown where the registry gives one.
Centre Hospitalier Universitaire Amiens-Picardie
Amiens, France · Recruiting
CH Annecy
Annecy, France · Recruiting
Centre Hospitalier Universitaire de Besançon
Besançon, France · Recruiting
Centre Hospitalier Bourgoin-Jallieu
Bourgoin, France · Recruiting
University Hospital of Dijon
Dijon, France · Recruiting
Centre Georges François Leclerc
Dijon, France · Recruiting
Centre Hospitalier Universitaire de Grenoble
La Tronche, France · Recruiting
Centre Hospitalier Universitaire de Lille
Lille, France · Recruiting
Centre lyonnais de chirurgie digestive
Lyon, France · Recruiting
Centre Hospitalier Lyon-Sud
Lyon, France · Recruiting
Hôpiatl Européen
Marseille, France · Recruiting
Hôpital La Timone
Marseille, France · Recruiting
Institut Paoli Calmettes
Marseille, France · Not yet recruiting
Hôpital Nord AP-HM
Marseille, France · Recruiting
Hôpital St Joseph Marseille
Marseille, France · Recruiting
CHU de Nancy
Nancy, France · Recruiting
Hôpital Saint Louis
Paris, France · Recruiting
Hôpital Saint Antoine
Paris, France · Recruiting
Hôpital Cochin
Paris, France · Recruiting
Hôpital Bicêtre
Paris, France · Recruiting
Hôpital Européen Georges Pompidou
Paris, France · Recruiting
Centre Hospitalier de Pontoise
Pontoise, France · Recruiting
Hôpital Robert Debré
Reims, France · Recruiting
Ch Pontchaillou
Rennes, France · Recruiting
Centre Hospitalier Universitaire de Rouen
Rouen, France · Recruiting
Santé Atlantique
Saint-Herblain, France · Recruiting
Centre Hospitalier Universitaire de Strasbourg
Strasbourg, France · Not yet recruiting
CHU de Toulouse
Toulouse, France · Recruiting
Clinique TIVOLI
Toulouse, France · Recruiting
Centre Hospitalier de Tours
Tours, France · Recruiting
Institut cancérologie de Lorraine
Vandœuvre-lès-Nancy, France · Recruiting
Gustave Roussy
Villejuif, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.